Primary central nervous system post-transplantation lymphoproliferative disorder: An international primary central nervous system lymphoma collaborative group report

Cancer

Volumn 116, Issue 4, 2010, Pages 863-870

  Cavaliere, Robert ^a   Petroni, Gina ^b   Lopes, Maria B ^c   Schiff, David ^c   O'Neill, Brian P ^d   Plotkin, Scott R ^d   Van Imhoff, Gustaaf W ^d   Neuwelt, Edward A ^d   Jahnke, Kristoph ^d   Raizer, Jeffrey J ^d   Villano, J Lee ^d   Abrey, Lauren E ^d   Batchelor, Tracy T ^d   Illerhaus, Gerald ^d   Horning, Sandra J ^d  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d NONE

Author keywords

Central nervous system; Lymphoma; Post transplantation lymphoproliferative disorder; Rituximab; Transplantation

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISONE; RITUXIMAB; TEMOZOLOMIDE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN BIOPSY; CANCER SURVIVAL; CHILD; CLINICAL FEATURE; EPSTEIN BARR VIRUS; FEMALE; HEMISPHERE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIMARY CENTRAL NERVOUS SYSTEM POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; TREATMENT RESPONSE; WHITE MATTER;

ADOLESCENT; ADULT; AGE FACTORS; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; TIME FACTORS;

EID: 76249109162     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24834     Document Type: Article

References (30)

1. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol. 2005;56:155-167.
2. Harris NL, Swerdlow SH, Frizzera G, Knowles GM. Post-transplant lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:264-269.
3. Schneck SA, Penn I. Cerebral neoplasms associated with renal transplantation. Arch Neurol. 1970;22:226-233.
4. Phan TG, O'Neill BP, Kurtin PJ. Post-transplant primary CNS lymphoma. Neuro Oncol. 2000;2:229-238.
5. Snanoudj R, Durrbach A, Leblond V, et al. Primary brain lymphomas after kidney transplantation: presentation and outcome. Transplantation. 2003;76:930-937.
6. Castellano-Sanchez AA, Li S, Qian J, Lagoo A, Weir E, Brat DJ. Primary central nervous system post-transplant lymphoproliferative disorders. Am J Clin Pathol. 2004;121: 246-253.
7. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
8. Buell JF, Gross TG, Hanaway MJ, et al. Post-transplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc. 2005;37:954-955.
9. Schiff D, O'Neill B, Wijdicks E, Antin JH, Wen PY. Gliomas arising in organ transplant recipients: an unrecognized complication of transplantation? Neurology. 2001;57:1486-1488.
10. Rosenow JM, Hirschfeld A. Utility of brain biopsy in patients with acquired immunodeficiency syndrome before and after introduction of highly active antiretroviral therapy. Neurosurgery. 2007;61:130-140; discussion 140-131.
11. Lim WH, Russ GR, Coates PT. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder postsolid organ transplantation. Nephrology (Carlton). 2006;11:355-366.
12. Shroff R, Rees L. The post-transplant lymphoproliferative disorder-a literature review. Pediatr Nephrol. 2004;19:369-377.
13. O'Neill BP, Vernino S, Dogan A, Giannini C. EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. Neuro Oncol. 2007;9:364-369.
14. Jamali FR, Otrock ZK, Soweid AM, et al. An overview of the pathogenesis and natural history of post-transplant Tcell lymphoma. Leuk Lymphoma. 2007;48:1237-1241.
15. Rees L, Thomas A, Amlot PL. Disappearance of an Epstein-Barr virus-positive post-transplant plasmacytoma with reduction of immunosuppression. Lancet. 1998;352: 789.
16. Diamond C, Taylor TH, Im T, Miradi M, Wallace M, Anton-Culver H. Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin's lymphoma. Curr HIV Res. 2006;4:375-378.
17. Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS. 2003;17:1787-1793.
18. Roychowdhury S, Peng R, Baiocchi RA, et al. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res. 2003;63:965-971.
19. Faller DV, Mentzer SJ, Perrine SP. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol. 2001;13:360-367.
20. Corn BW, Donahue BR, Rosenstock JG, et al. Palliation of AIDS-related primary lymphoma of the brain: observations from a multi-institutional database. Int J Radiat Oncol Biol Phys. 1997;38:601-605.
21. Jacomet C, Girard PM, Lebrette MG, Farese VL, Monfort L, Rozenbaum W. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS. 1997;11:1725-1730.
22. Taj MM, Messahel B, Mycroft J, et al. Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children. Br J Haematol. 2008;140:191-196.
23. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;107:3053-3057.
24. Gonzalez-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica. 2007;92:1489-1494.
25. Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25:4730-4735.
26. Ruhstaller TW, Amsler U, Cerny T. Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol. 2000;11:374-375.
27. Traum AZ, Rodig NM, Pilichowska ME, Somers MJ. Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients. Pediatr Transplant. 2006;10:505-512.
28. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165-2170.
29. Maecker B, Jack T, Zimmermann M, et al. CNS or bone marrow involvement as risk factors for poor survival in posttransplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol. 2007;25:4902-4908.
30. Caillard S, Lelong C, Pessione F, Moulin B. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant. 2006;6:2735-2742.